US FDA Approves Regeneron Therapy

The US Food and Drug Administration has approved Regeneron Pharmaceuticals drug for adults with generalized myasthenia gravis. The treatment is intended for patients who test positive for specific antibodies.

Insights:
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo

Regeneron Pharmaceuticals won approval from the United States Food and Drug Administration to treat adults with generalized myasthenia gravis on Thursday evening. The treatment targets patients who test positive for anti-acetylcholine receptor antibodies. The regulatory clearance expands the drug's label into a new neuromuscular indication.